WO2009084069A2 - Solution oculaire avec du lycopène organique - Google Patents

Solution oculaire avec du lycopène organique Download PDF

Info

Publication number
WO2009084069A2
WO2009084069A2 PCT/IT2008/000793 IT2008000793W WO2009084069A2 WO 2009084069 A2 WO2009084069 A2 WO 2009084069A2 IT 2008000793 W IT2008000793 W IT 2008000793W WO 2009084069 A2 WO2009084069 A2 WO 2009084069A2
Authority
WO
WIPO (PCT)
Prior art keywords
solutions according
derivatives
hyaluronic acid
vitamin
lycopene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2008/000793
Other languages
English (en)
Other versions
WO2009084069A4 (fr
WO2009084069A3 (fr
Inventor
Leonardo Rescio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LIO FARMACEUTICI Srl
Original Assignee
LIO FARMACEUTICI Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIO FARMACEUTICI Srl filed Critical LIO FARMACEUTICI Srl
Publication of WO2009084069A2 publication Critical patent/WO2009084069A2/fr
Publication of WO2009084069A3 publication Critical patent/WO2009084069A3/fr
Publication of WO2009084069A4 publication Critical patent/WO2009084069A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Definitions

  • the present invention has as subject pharmaceutical compounds useful as eyewash and/or tear substitute comprising carotenoids such as natural lycopene and/or organic lycopene, lutein, zeaxanthine, astaxanthine, plant and synthetic lipids, phospholipids and linear and/or cross-linked hyaluronic acid and/or its salts or other viscosifying agents (for example carboxymethylcellulose, carbomer, and the like).
  • carotenoids such as natural lycopene and/or organic lycopene, lutein, zeaxanthine, astaxanthine, plant and synthetic lipids, phospholipids and linear and/or cross-linked hyaluronic acid and/or its salts or other viscosifying agents (for example carboxymethylcellulose, carbomer, and the like).
  • carotenoids such as natural lycopene and/or organic lycopene, lutein, zeaxanthine, astaxanthine, plant
  • compositions of the invention are also useful both as per se active ingredients (for the treatment of retinal degenerations, like the diabetic retinal degeneration or AMD - Age-related macular degeneration), and as cicatrizants and/or carriers for other active ingredients in ophthalmology (for example antibiotics or cortisones or NSAIDs - Non-steroidal anti-inflammatory drugs).
  • the technical problem resolved by the present invention is the creation of a tear substitute and/or eyewash which, in addition to the typical characteristics of the tear substitutes consisting of hydrating, lubricating and moistening capacity/effect, has further characteristics linked to the anti-oxidant activity of the carotenoids and the specific UVA/UVB radiation absorption activity of organic lycopene.
  • Dry eye syndrome is an eye disease characterised by the alteration of the natural lachrymal film, with serious discomfort and annoyance by the subject affected with such disorder.
  • There are multiple causes of this disease in particular phenomena tied to aging, environmental and atmospheric factors, use of contact lenses, autoimmune pathologies, trigeminal paralysis, oncological diseases, systemic pharmacological therapies, eye surgery operations (for example, various laser therapies or cornea transplants, palpebral operations or operations on the nerve ending level). Dry eye syndrome is currently treated systemically or topically.
  • Systemic treatments are known at the state of the art comprising, for example, oral compositions based on unsaturated fatty acids (US7029712) or cysteine (WO02055068).
  • tear substitutes are used in the form of eyewash or gel based on detergent, lubricating and possibility disinfecting compounds. Nevertheless, these products only act on the symptomatological level, and sometimes the preservatives contained therein tend to worsen the condition rather than resolve it.
  • Treatments are also known at the state of the art which use glucocorticoids, like rimexolone (EPl 575597; US2006069075) and other anti-inflammatory agents (U.S. 6.506.412) for the treatment of possible inflammatory processes underlying the dry eye syndrome.
  • Antibiotics are also used, for example tricyclic macrolide compounds (WO0066122) or peptides like duramycin (US2006035811).
  • the present invention regards topical compositions comprising the association of carotenoids (organic lycopene) with phospholipids and/or plant or synthetic lipids with a viscoelastic agent, in particular as a tear substitute.
  • carotenoids organic lycopene
  • phospholipids and/or plant or synthetic lipids with a viscoelastic agent in particular as a tear substitute.
  • This combination of substances has shown to be particularly effective in the topical treatment of the dry eye syndrome and of the retinal degenerations, such as for example diabetic retinopathy or AMD (Age-related macular degeneration).
  • the compositions of the invention are also useful as carriers or as preservatives for other active ingredients. Said compositions have activities favouring the cicatrising or tissue regeneration processes.
  • the composition of the tear substitute containing organic lycopene, subject of the present invention is also capable of protecting the eye from dangerous UVAAJVB radiations.
  • carotenoids comprise lycopene, lutein, zeaxanthine, astaxanthine, which can be used on their own or mixed with each other, each in percentages by weight generally in the range of 0.001 - 1%, preferably 0.01 - 0.5%.
  • the plant lipids such as for example olive oil and/or almond oil, are present in the compositions of the invention in percentages by weight generally in the range of 0.001 - 5%, preferably 0.001 - 4%. Said lipids can also be of synthetic origin.
  • the phospholipids which can be employed according to the invention comprise soy lecithin or egg lecithin, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, polar lipid complexes (for example glycosyl ceramides and digalactosyl glycerides, etc.), various plant seed extracts and/or their mixtures in all proportions.
  • the percentages by weight of said phospholipids or phospholipid mixtures or various lipid mixtures in the compositions of the invention vary from 0.001 to 10%.
  • compositions of the invention contain linear and/or cross-linked hyaluronic acid and/or its salts at a concentration in the range of 0.001% - 10% by weight, depending on the molecular weight, variable from 200 kDalton to 30 MDalton: a greater molecular weight corresponds with a smaller concentration, and vice versa.
  • compositions of the present invention can moreover contain linear and/or cross- linked hyaluronic acid and/or its salts, saturated or unsaturated fatty acids, antioxidant agents (Vitamin A, Vitamin E, Vitamin C, Resveratrol etc.), honey/royal jelly, antibiotics, antiinflammatory agents, cortisones and other active and/or proactive ingredients, Aloe vera extracts.
  • the compositions of the present invention can may also contain or not a buffer solution. Said buffer solution, where existing, can be citrate, phosphate, borate or other.
  • the present invention also has as subject the use of carotenoids (for example lycopene, lutein, zeaxanthine and/or astaxanthine), free or encapsulated in liposomes/cerasomes, in association with phospholipids and/or plant or synthetic lipids with linear and/or cross-linked hyaluronic acid and/or its salts, for the preparation of medications with cicatrizant/tissue repair activity in ophthalmology.
  • carotenoids for example lycopene, lutein, zeaxanthine and/or astaxanthine
  • association of the invention can be used as a carrier and preservative for active ingredients of ophthalmic interest, for example beta-blocking (timolol, carteolol, etc.), prostaglandin, glucocorticoids, antibiotics, membrane stabilisers, metals, plant extracts (in particular Aloe vera, Ginkgo biloba).
  • active ingredients of ophthalmic interest for example beta-blocking (timolol, carteolol, etc.), prostaglandin, glucocorticoids, antibiotics, membrane stabilisers, metals, plant extracts (in particular Aloe vera, Ginkgo biloba).
  • the compositions of the invention can be formulated according to well-known conventional methods, such as those described in "Remington's Pharmaceutical Handbook" Mack Publishing Co., N. Y., USA, using excipients, diluents, viscosifiers, isotonic agents and similar substances acceptable for their final use.
  • viscoelastic substances will be advantageously used, such as sodium hyaluronate, polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropylmethylcellulose, polyacrylic acids (Carbopol), and beta-glucan.
  • suitable formulations comprise eyewashes, sterile eye drops, gel, foams and ointments.
  • Plant lipids (olive oil and/or almond oil) 2 Phosphatidylcholine (50%)-Phosphatidylserine (50%) 5
  • Vitamin A 0.1 Vitamin E 0.1
  • Plant lipids (olive oil and/or almond oil) 2
  • Plant lipids (olive oil and/or almond oil) 2 Vitamin E 0.1 Cross-linked and/or linear hyaluronic acid and/or its salts ⁇ 5
  • Hydroxypropylmethylcellulose (Hypromellose-HPMC) ⁇ 5
  • Lactated Ringer's Solution (F.U.) 1 WFI bidistilled water q.s. to 100
  • Hydroxypropylmethylcellulose (Hypromellose-HPMC) ⁇ 5
  • Lactated Ringer's Solution (F.U.) 1 WFI bidistilled water q.s. to 100
  • Plant lipids (olive oil and/or almond oil) 4
  • Plant lipids (olive oil and/or almond oil) 4
  • Plant lipids (olive oil and/or almond oil) 2
  • Resveratrol 0.1 Cross-linked and/or linear sodium hyaluronate
  • Plant lipids (olive oil and/or almond oil) 2 WFI bidistilled water q.s. to 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une solution oculaire topique comportant des caroténoïdes, des liposomes, des lipides végétaux /cérasomes, des phospholipides et des agents de viscosité.
PCT/IT2008/000793 2008-01-02 2008-12-23 Solution oculaire avec du lycopène organique Ceased WO2009084069A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000003A ITMI20080003A1 (it) 2008-01-02 2008-01-02 Composizioni per uso oftalmico
ITMI2008A000003 2008-01-02

Publications (3)

Publication Number Publication Date
WO2009084069A2 true WO2009084069A2 (fr) 2009-07-09
WO2009084069A3 WO2009084069A3 (fr) 2009-09-17
WO2009084069A4 WO2009084069A4 (fr) 2009-11-05

Family

ID=40290036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2008/000793 Ceased WO2009084069A2 (fr) 2008-01-02 2008-12-23 Solution oculaire avec du lycopène organique

Country Status (2)

Country Link
IT (1) ITMI20080003A1 (fr)
WO (1) WO2009084069A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138228A1 (fr) * 2010-05-04 2011-11-10 Trb Chemedica Ag Composition aqueuse pour utilisation ophtalmique ou cutanée
ITMI20110849A1 (it) * 2011-05-13 2012-11-14 Farmila Thea Farmaceutici Spa Preparazioni oftalmiche in forma di collirio e loro uso
WO2013096173A1 (fr) * 2011-12-21 2013-06-27 Novartis Ag Lentilles de contact contenant un caroténoïde et leur procédé de fabrication
US20140341967A1 (en) * 2009-02-18 2014-11-20 Eyeon Particle Sciences Llc Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications
EP3085365A3 (fr) * 2009-01-19 2017-01-04 Lycored Ltd. Combinaisons synergiques de caroténoïdes et de polyphénols
CN107249678A (zh) * 2014-12-19 2017-10-13 凯敏工业公司 使用离子电渗法进行生物活性分子的眼内递送
EP3203993A4 (fr) * 2014-10-10 2018-05-23 Peter F. Kador Collyre antioxydant
EP3682867A1 (fr) * 2019-01-16 2020-07-22 Taipei Medical University Composition ophtalmique contenant de la lutéine
RU2745124C1 (ru) * 2020-07-02 2021-03-22 Общество с ограниченной ответственностью "МедикалСайнс" Биоактивная композиция на основе сшитой соли гиалуроновой кислоты, содержащая ресвератрол, и способ ее получения
US11135242B2 (en) 2016-07-06 2021-10-05 Calm Water Therapeutics Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
IT202100006839A1 (it) * 2021-03-22 2022-09-22 Omisan Farm S R L Preparato topico oftalmico idrosolubile contenente luteina e relativo metodo di produzione
KR20220162858A (ko) * 2020-04-27 2022-12-08 쿠퍼비젼 인터내셔널 리미티드 항산화 콘택트 렌즈
EP4218717A1 (fr) * 2022-02-01 2023-08-02 Laboratoires THEA Composition ophtalmique comprenant du resvératrol pour traiter le syndrome de l' il sec

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920003601B1 (ko) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
FR2895257A1 (fr) * 2005-12-22 2007-06-29 Oreal Actif pour le traitement du contour des yeux.

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3085365A3 (fr) * 2009-01-19 2017-01-04 Lycored Ltd. Combinaisons synergiques de caroténoïdes et de polyphénols
US20140341967A1 (en) * 2009-02-18 2014-11-20 Eyeon Particle Sciences Llc Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications
US9295693B2 (en) * 2009-02-18 2016-03-29 Eyeon Particle Sciences Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
US12280073B2 (en) 2009-02-18 2025-04-22 Calm Water Therapeutics Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
US11110119B2 (en) 2009-02-18 2021-09-07 Calm Water Therapeutics Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
US9884074B2 (en) 2009-02-18 2018-02-06 Eyeon Particle Sciences Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
WO2011138228A1 (fr) * 2010-05-04 2011-11-10 Trb Chemedica Ag Composition aqueuse pour utilisation ophtalmique ou cutanée
ITMI20110849A1 (it) * 2011-05-13 2012-11-14 Farmila Thea Farmaceutici Spa Preparazioni oftalmiche in forma di collirio e loro uso
WO2013096173A1 (fr) * 2011-12-21 2013-06-27 Novartis Ag Lentilles de contact contenant un caroténoïde et leur procédé de fabrication
US8784867B2 (en) 2011-12-21 2014-07-22 Novartis Ag Contact lenses containing carotenoid and method for making same
JP2015509205A (ja) * 2011-12-21 2015-03-26 ノバルティス アーゲー カロテノイドを含有するコンタクトレンズ及びその製造方法
EP3203993A4 (fr) * 2014-10-10 2018-05-23 Peter F. Kador Collyre antioxydant
EP3233174A4 (fr) * 2014-12-19 2018-08-01 Kemin Industries, Inc. Administration intraoculaire de molécules bioactives par iontophorèse
JP2020121998A (ja) * 2014-12-19 2020-08-13 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
CN107249678A (zh) * 2014-12-19 2017-10-13 凯敏工业公司 使用离子电渗法进行生物活性分子的眼内递送
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
US11135242B2 (en) 2016-07-06 2021-10-05 Calm Water Therapeutics Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
EP3682867A1 (fr) * 2019-01-16 2020-07-22 Taipei Medical University Composition ophtalmique contenant de la lutéine
US11426346B2 (en) * 2019-01-16 2022-08-30 Taipei Medical University Lutein-containing ophthalmic composition
KR102545933B1 (ko) 2020-04-27 2023-06-22 쿠퍼비젼 인터내셔널 리미티드 항산화 콘택트 렌즈
KR20220162858A (ko) * 2020-04-27 2022-12-08 쿠퍼비젼 인터내셔널 리미티드 항산화 콘택트 렌즈
RU2745124C1 (ru) * 2020-07-02 2021-03-22 Общество с ограниченной ответственностью "МедикалСайнс" Биоактивная композиция на основе сшитой соли гиалуроновой кислоты, содержащая ресвератрол, и способ ее получения
WO2022201211A1 (fr) * 2021-03-22 2022-09-29 Omisan Farmaceutici S.R.L. Préparation ophtalmique topique soluble dans l'eau contenant de la lutéine et son procédé de production
IT202100006839A1 (it) * 2021-03-22 2022-09-22 Omisan Farm S R L Preparato topico oftalmico idrosolubile contenente luteina e relativo metodo di produzione
EP4218717A1 (fr) * 2022-02-01 2023-08-02 Laboratoires THEA Composition ophtalmique comprenant du resvératrol pour traiter le syndrome de l' il sec
WO2023148180A1 (fr) 2022-02-01 2023-08-10 Laboratoires Thea Composition ophtalmique comprenant du resvératrol pour le traitement du syndrome de l'œil sec

Also Published As

Publication number Publication date
WO2009084069A4 (fr) 2009-11-05
ITMI20080003A1 (it) 2009-07-03
WO2009084069A3 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
WO2009084069A2 (fr) Solution oculaire avec du lycopène organique
JP6757435B2 (ja) 眼科用水性組成物
RU2756758C2 (ru) Офтальмологические композиции
JP5673531B2 (ja) 眼科用組成物
AU2008354558B2 (en) Stable ophthalmic formulations
WO2018071619A1 (fr) Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation
EP2664330A1 (fr) Composition et médicament comprenant des acides gras oméga 3 ainsi qu'un glycosaminoglycane
JP5800072B2 (ja) 眼科用組成物及び白濁・沈殿抑制方法
KR101690816B1 (ko) 안과용 조성물 및 백탁·침전 억제 방법
EP2057983A1 (fr) Compositions pour la protection topique des tissus oculaires à partir des effets nuisibles des rayonnements à ultraviolets
EP4039248B1 (fr) Composition ophtalmique
JP5681472B2 (ja) 眼科用組成物
EP1891939B1 (fr) Compositions comprenant des composés ammonium quaternaires
EP3888634B1 (fr) Formulation ophtalmique et son utilisation
EP4652992A1 (fr) Composition ophtalmique pour prévenir et traiter les lésions de l'épithélium conjonctivite et l'inconfort associé provoqué par des formulations hypotonantes
Singh Review of various lacrimomimetics: making the appropriate choice
IT202100013787A1 (it) Composizione per l’uso nel trattamento di affezioni oculari, quali sindrome dell’occhio secco, specialmente post-chirurgico oftalmico / a composition for use in the treatment of ocular affections, such as dry eye disease, especially after eye surgery
IT202000015457A1 (it) Composizione oftalmica e suo uso nel trattamento di patologie dell’occhio
JP6077860B2 (ja) 液剤
ITMI20072135A1 (it) Composizioni per la protezione topica dei tessuti oculari dagli effetti dannosi delle radiazioni ultraviolette
HK1112409B (en) Compositions containing quaternary ammonium compounds

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: MI2008A000003

Country of ref document: IT

Date of ref document: 20100701

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08868584

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08868584

Country of ref document: EP

Kind code of ref document: A2